Peptides of 100 to 200 residues can be produced by chemical synthesis instead of recombinant expression when stepwise solid-phase peptide synthesis is combined with fragment ligation. This guide covers the underlying chemistry, realistic purity and timeline expectations from documented production…
Peptides longer than 100 amino acids can be made by chemical synthesis, but not by the same process used for a 20-residue peptide. The route has two stages: stepwise solid-phase peptide synthesis SPPS to assemble the chain, or fragments of it, and chemical ligation to join purified fragments into the final product. For a suitable sequence, the 100 to 200 residue range is within reach, at purities from roughly 83% for a 169-residue chain to above 95% for shorter targets, and on timelines around 4 weeks. The binding constraint is sequence, not length: a repetitive polyglutamine-rich chain of 60 to 80 residues can defeat synthesis where a compositionally balanced chain twice as long succeeds.
This size range matters for questions that short peptides cannot answer. The same chain length that is routine for a folded domain is the point at which stepwise chemistry alone stops being reliable. Protein-receptor binding, domain interfaces, and functions that depend on the folded architecture of a whole domain require chains on the order of 100 to 200 amino acids, roughly the size of an average protein domain. For many research projects, a synthetic long peptide is a direct alternative to cloning and overexpression workflows, bypassing the expression host entirely. The practical question a researcher brings to a synthesis vendor is usually concrete: can this sequence be made, how pure will it get, how long will it take, and what will fail? The evidence reviewed here, drawn from one vendor's published production record and from the peptide synthesis literature, gives concrete answers and marks where the evidence runs out.
Solid-phase peptide synthesis is the most widely used method for making peptides, and it is the starting point for anything longer. The C-terminus of the first amino acid is coupled to an activated solid support, typically a polystyrene resin, which serves as the C-terminal protecting group and allows the growing peptide to be separated from reaction mixtures by filtration and washing. Amino acids are added one at a time, each coupling driven toward completion by excess reagent, followed by deprotection and washes before the next residue. Most routine SPPS today uses Fmoc chemistry, with a base-labile temporary protecting group; the older Boc/Bzl scheme, removed under acidic conditions, is the alternative and, as discussed below, is often favored for long or difficult sequences.
The limit of stepwise SPPS is well documented. A 2015 review of solid-phase protein chemical synthesis puts the practical ceiling of SPPS at about 50 amino acids PMID 25791484 . That ceiling is not fixed. A 2022 review of automated peptide synthesizers notes that advances in instrumentation and chemistry have enabled preparation of peptides exceeding 150 amino acid residues PMID 35601548 . The reason the ceiling moves slowly is that every coupling step has a small failure rate, deletion impurities accumulate down the chain, and the resin-bound chain becomes increasingly prone to aggregation that blocks access of incoming amino acids.
For the 100 to 200 residue range, the standard engineering solution is fragment ligation. Intermediate fragments are assembled by stepwise SPPS, purified in unprotected form, and then joined chemically with minimal side-chain protection. The foundational method is native chemical ligation , demonstrated in 1994 with the one-step synthesis of a cytokine containing multiple disulfides from two unprotected segments, which join through a thioester-linked intermediate that rearranges to a native peptide bond PMID 7973629 . Adaptation of this chemistry to the solid phase itself has been described PMID 25791484 . The largest peptide in the production record discussed below was made exactly this way, with SPPS-derived fragments joined by chemical ligation.
Ligation brings its own constraints. The junction between fragments must be chosen so that the joining reaction yields a native peptide bond, and each fragment must be long enough to purify cleanly yet short enough to assemble without the aggregation problems of a full-length chain. The vendor record does not disclose the junction design for the 169-residue peptide, so the strategic choices that shaped that synthesis are not publicly known.
LifeTein, a custom peptide synthesis vendor, publishes production case examples with quantified outcomes. The largest is a 169-residue peptide with a molecular weight of 18716.41 Da, produced at 83% HPLC purity within 4 weeks. That number should be read carefully: 83% homogeneity is below the threshold most labs set for quantitative biochemistry, but for a chain of nearly 170 residues it is a working product for interaction studies and biophysical screens, and it arrived faster than a typical cloning, expression, and purification campaign.
A very hydrophobic 68-residue peptide with an N-terminal FITC modification was produced at its 85% purity target, also within 4 weeks. Hydrophobicity is one of the classic drivers of resin aggregation and purification difficulty, so this example shows that moderate-length targets can be slow when the composition is unfavorable, even when the length is otherwise unremarkable.
Shorter targets reached higher purity. A 97-residue peptide designated mB Box-97syn was delivered at greater than 95% homogeneity by HPLC, which the vendor notes enabled larger-scale production. A 54-residue peptide corresponding to the HCD core region of human IRF2BPL, spanning amino acids 395 to 448, was synthesized with N-terminal acetylation and C-terminal amidation at greater than 95% purity; the vendor reports that it was used in a 2026 Nature Communications study of NEDAMSS syndrome-related mutations and aberrant liquid-liquid phase separation of IRF2BPL. A 76-residue peptide corresponding to the mature form of BfUbb, with the signal sequence removed, rounds out the list.
A 133-residue peptide designated SHT illustrates what a synthetic chain can carry in a single molecule: a cell-penetrating peptide domain, a secretion signal sequence, a DNA-binding domain, and other SHT features. The vendor supplied this peptide in connection with patent-related materials on nucleic acid vectors and hybrid proteins for DNA binding, transfection, and transformation studies. These are exactly the kinds of sequences that often express poorly in bacteria, because DNA-binding and membrane-active domains are prone to insolubility and toxicity in E. coli.
Across these examples the pattern is consistent: targets in the 50 to 100 residue range reached above 95% homogeneity, while the 169-residue chain reached 83% and the difficult 68-residue hydrophobic chain reached its 85% target. Purity expectations should track length and sequence difficulty together, not length alone.
The single most important variable in long-peptide synthesis is sequence composition, and polyglutamine-rich sequences are the canonical hazard. Consecutive glutamine residues promote hydrogen bonding and resin aggregation, which leads to incomplete coupling, deletion impurities, and difficult HPLC purification. The mechanism is direct: glutamine side chains form extended networks of hydrogen bonds, and a resin-bound chain of such residues collapses into a partially aggregated state that sterically blocks incoming activated amino acids. The hydrogen-bonding networks that drive designed peptide self-assembly in solution are the same interactions that cause this failure on resin.
The vendor's comparative claims follow from this mechanism. A repetitive peptide of only 60 to 80 amino acids can be more difficult to synthesize than a longer peptide with balanced amino acid composition, and some 150-residue peptides yield better results than some 70-residue peptides. Both statements are plausible given the chemistry, and both are warnings: a promise that a target is easy because it is short deserves skepticism when the sequence is low-complexity.
Cleavage is the second major hazard. Reactive intermediates generated during deprotection and cleavage from the resin can damage vulnerable residues, particularly arginine, aspartate, and glutamate. This is one reason long, difficult, or base-sensitive sequences are often better served by Boc/Bzl protection chemistry. In Boc/Bzl chemistry the temporary alpha-amino protection is a tert-butyloxycarbonyl group, side chains are masked as benzyl-type derivatives, and both are removed under strongly acidic conditions; the scheme avoids the base exposure of Fmoc chemistry and, in the vendor's account, reduces damage to sensitive side chains. The vendor's proprietary PeptideSyn production technology is claimed to reduce these challenges further, but its specific mechanism is not disclosed, so the claim cannot be independently checked.
Chemical synthesis also buys access to structures that no expression system can produce directly. D-amino acids can be incorporated in a regular fashion, and artificial amino acids with isosteric side chains can probe the functional importance of specific residues. The literature shows the same principle with post-translational modifications: an Fmoc-based protocol using phosphoribosylated glutamine, asparagine, and citrulline building blocks generates mono-ADP-ribosylated peptides with the modification at defined positions PMID 30097880 . None of these options exist in a recombinant workflow without substantial engineering.
The case for chemical synthesis is strongest when the target sequence is hostile to E. coli. The vendor enumerates the classic failures of recombinant production: poor expression, cloning errors, affinity tags such as FLAG or 6-His that must be cleaved and removed, and mis-translation of codons that are rare in prokaryotic hosts. For a 100 to 200 residue peptide, the chemical route can be faster and more direct than cloning, overexpressing, and tag removal, especially when the experiment needs only milligrams of material for binding or biophysical work.
The comparison cuts both ways. Recombinant expression scales to gram quantities and remains the only practical route to proteins of several hundred residues, and it can, in the right host, provide eukaryotic post-translational processing. Chemical synthesis cannot economically produce a 400-residue multidomain protein. The 100 to 200 residue window is where the two methods genuinely compete, and the choice is driven by sequence, quantity, modifications, and timeline. When the experiment requires a defined post-translational modification, a D-amino acid at a specific position, or a dye label, synthesis is the only clean route. Chemical synthesis also makes it straightforward to order a series of single-residue variants or analogues with unnatural side chains without rebuilding an expression construct for each one.
Synthetic access underpins discovery workflows that depend on systematic variation. Peptide libraries and virtual screening of chemical space were used in an antimicrobial peptide development project PMID 39488750 , where the libraries were virtual and only a few tens of selected compounds were then synthesised.
When requesting a peptide over 100 residues, provide the sequence, desired purity, quantity, and any modifications. The vendor then selects between SPPS, hybrid synthesis, or an alternative sequence-specific strategy. A vendor should be able to identify, before synthesis begins, which regions of the sequence create aggregation or coupling risk. The typical workflow for a long target is an in silico analysis of aggregation risk and difficult regions, fragment design if ligation is needed, SPPS of fragments, ligation, purification, and quality control. A realistic timeline from the production record is around 4 weeks for challenging targets, which is competitive with a rushed expression campaign and far shorter than a difficult one.
Quality control follows a default that buyers should understand before ordering. Long peptides are HPLC-purified and confirmed by ESI mass spectrometry, but net peptide content is not measured by amino acid analysis unless specifically requested. This distinction matters: an HPLC purity of 85% measures homogeneity, the fraction of material that elutes as the main peak, not the absolute peptide mass fraction in the powder. Counterions and residual solvents are not accounted for in that number. If the downstream assay is quantitative, request amino acid analysis and treat the vendor's purity figure as an upper bound on useful peptide content.
For difficult sequences, state the intended use. Boc/Bzl protection is the vendor's recommended chemistry for long, difficult, or base-sensitive sequences, and it is worth asking which chemistry will be used for a given target. For labeled long peptides, such as the FITC-modified 68-residue example, confirm whether the label is added during assembly or after ligation, since that choice affects purification. For confidential sequences, the vendor states that analytical HPLC and MS data can be displayed without disclosing the underlying sequence, which gives a blinded project verifiable quality evidence. Expect trouble with polyglutamine-rich material even at relatively short lengths, and ask the vendor directly what length and purity were achieved on previous low-complexity targets, since that is where the public record is thinnest.
The vendor record is useful but limited. PeptideSyn and the vendor's AI-assisted design and manufacturing workflow are asserted to support challenging long-peptide projects, but neither is described in enough technical detail for independent evaluation. There is no disclosed mechanism, no comparative data against conventional SPPS, and no third-party replication. The claim that 100 to 200 residue synthesis is achievable for suitable sequences is explicitly sequence-qualified, which implies that not every target in that range is accessible, and the record does not say what fraction of requests succeed. Quantities delivered are not part of the public record for these examples, so the purity and timeline figures cannot be tied to a specific scale.
The polyglutamine case study is a notable gap. The vendor flags an aggregation-prone, low-complexity peptide with extended polyglutamine-rich and alanine-rich segments as a demonstration that such material can be produced, with HPLC and MS evidence hosted on a separate page. The length and final purity of that peptide are not stated in the source, which is precisely the information a researcher with a polyQ target needs. Given the vendor's own claim that a 60 to 80 residue repetitive peptide can be harder than a well-balanced 150-residue one, the missing number is not an academic detail.
Buyers should also note the absence of a market comparison. The record does not say whether 100 to 200 residue synthesis is broadly available across vendors or specific to one company's process, and a capability claim should be treated as a claim, not a baseline. Ask a prospective vendor for documentation of comparable projects: length, achieved purity, delivery time, and the sequence class involved. Finally, read the purity figures with the QC caveat in mind. HPLC homogeneity and ESI mass confirmation verify the main species, but they do not quantify deletion impurities that are difficult to resolve, and they do not measure net peptide content. For quantitative work, amino acid analysis is not optional.
Related reading: Tag-Assisted Peptide Synthesis: How TAPS Works and Its Benefits, API Contract Manufacturing: Process, Benefits, and Partner Selection, Manual Fmoc Solid-Phase Peptide Synthesis: A Beginner's Protocol, Peptide CoA: What HPLC Purity and LC-MS Actually Prove.